France).Column chromatography was performed on silica for chromatography: Silicagel 60 (40-63 µm) Geduran Si60 (Merck, Darmstadt, Germany) .The progress of all reactions and column chromatography was monitored by thin-layer chromatography (TLC). TLC was performed with Merck silica gel 60 F254 pre-coated plates and visualized by UV absorption and/or stained with a solution of vanillin -H 2 SO 4 stain, Dragendorff reagent, ninhydrin or iodine vapors. 1 H and 13 C NMR spectra were recorded on a Bruker Ultrashield plus 400
Spectrometer (operated at 400 or 100 MHz). The 1 H NMR chemical shifts are reported in parts per million, using the signal for residual solvent protons (7.27 for CDCl 3 , 3.31 for were dissolved in dichloromethane (200 mL) and purged with argon. 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.49 eq, 8.3 g, 43.3 mmol; Mw 191.7) was added as a solid, followed by slow drop-wise addition of dry N,N-diisopropylethylamine (1.49 eq, 7 mL, 5.18 g, 40 mmol). The mixture was stirred overnight at room temperature in brown glassware, which protects the reagents from light. Solvents and excess amine were evaporated in a rotary evaporator, then dissolved again in dichloromethane (200 mL) and extracted with distilled water (100 mL). Aqueous phase was re-extracted with dichloromethane (200 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered on a paper disc under vacuum, evaporated in a rotary evaporator and dried under vacuum The obtained white solid (12.54 g, 26.6 mmoles, Mw 471.67 ) is the expected NHS ester obtained in quantitative yield was confirmed by NMR analysis.
This activated hydroxysuccinimidyl ester was used in the next step with no further purification.
The NHS ester (4.716 g, 10 mmoles, Mw 471.67) was dissolved in 200 mL dichloromethane (stabilized with amylene). 1,13-diamino-4,7,10-trioxatridecane (4.4 g, 20 mmoles, Mw 220.3), dissolved in 200 mL dichloromethane was added at room temperature. The reaction was stirred for 24 hours. Methanol (20 mL) was added to dissolve the formed precipitate. The reaction mixture was purified directly, without evaporation, on a silica gel column, equilibrated with 5% methanol and 0.5% NH 4 OH in dichloromethane (column with a diameter of 5 cm and 17 cm length 6, 76.5, 70.0, 69.7, 69.6, 69.0, 68.3, 65.0, 38.7, 36.3, 35.7, 31.7, 29.3-28.1, 26.7, 25.6, 22.3, 18.3, 13 .0 ppm.
High resolution mass spectroscopy coupled to liquid chromatography: LC-HRMS
Observed mass: 576.48527 (theoretical 576.48661; score 96.91%); 100% purity by LC-MS (from +ESI total ion current)
See Figure S3 : LC-HRMS analysis of the surfactant (1)
Formulation and physicochemical characterization Formulation and photopolymerization of Polydiacetylenic nanofibers
A concentrated solution of C 25 -diyne-trioxaamine was prepared by dissolving the amine in ethanol at 60°C under sonication (60 mg/6 mL). This warm solution was filtered through a cotton pad (in a glass pipette, to remove minor polymerized contaminants) and injected into ethanol-water (12 mL/42 mL) mixtures to obtain final 30% ethanolic solutions at a concentration of 1 mg/mL trioxaamine. This solution was placed at 5°C for 18 hours, where it transformed into an opaque gel-like suspension. UV-polymerization was performed on 5 mL 
UV-VIS spectra of Nanofibers
UV-Vis spectra were recorded with the double beam spectrometer Cary 100 Bio UV-Vis (ELO50-73007; Varian). Nanofiber suspensions were diluted in pure water (30 µg polymerized C 25 diyne-trioxaamine in 1 mL water). The absorption maxima were determined (lambda max.) from these spectra.
The red biologically active form has the following spectral characteristics: 
Fluorescence spectroscopy of PDA Nanofibers
Fluorescence emission and excitation spectra were recorded on Shimadzu
Spectrofluorophotometer RF-5301. The maximum excitation and excitation wavelengths were first determined in a step-wise approach. The corresponding excitation and emission spectra were then recorded using the most efficient excitation and emission wavelengths using the following parameters: the excitation spectrum was recorded from 400 nm to 630 nm, at the maximum emission wavelength of 646 nm. A split width of 10 nm for both emission and excitation, low sensitivity and slow scan speed were used as standard settings.
The emission spectrum was recorded from 565 nm to 800 nm at the maximum excitation of wavelength of 550 nm. A split width of 10 nm for both emission and excitation, low sensitivity and slow scan speed were used as standard settings.
Notably,a large energy gap (> 100 nm) separates fluorescence emission maximum from excitation maximum (Stokes shift). See Figure 2 (main text).
Size analysis by dynamic light scattering (DLS)
The mean size of the PDA-nanofibers was determined by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments). The samples were diluted in water (10 µg in 1 mL).
We used following settings for size determination and for zeta-potential measurement: Dynamic light scattering (DLS) and zeta potential measurement of the free PDA-Nfs.
The complexes formed with siLim and PDA-Nfs at N/P = 6 prepared under the same conditions as used for the in vivo studies were also extensively characterized by DLS and zeta potential measurements as described for the PDA-Nfs. The flocculation limit at N/P = 4 was explained by a drastic drop in the zeta potential to become negative for N/P = 2, as expected for complexes where the negatively charged groups resulting from excess siRNA predominate.
For the biophysical characterization of PDA-Nfs/siLim complexes prepared at the same conditions and buffer conditions (Hespes buffered glucose) as used for the in vivo see Figure   S11 : Biophysical characterization of siLim1/PDA-Nfs complexes.
Gel retardation assay
Fluorescently labelled siRNA (Cy5-siLuc, 23.8 pmoles siRNA, equivalent to 1000 pmoles phosphate groups 'P') were incubated within creasing amounts of PDA-nanofibers in Hepes Buffered Glucose (HBG, pH 7.5, completed to 20 µL). The resulting siRNA-nanofiber complexes have increasing N/P ratio ranging from 1/1 to 7/1. N/P ratios are defined by the number 'N' of amine groups from the trioxaamine Nanofibers (being positively charged), versus the number 'P' of negatively charged phosphate groups present in the siRNA (P).
Using a constant concentration of 23.8 pmoles siRNA an N/P = 1 ratio was obtained by adding 0.6 µL of the PDA-Nf solution (1 mg/mL, 1.6 mM) containing 1000 pmoles monomer. 
786-O cell line
The LGFP-Lim1 (InvivoGen, Toulouse, France) were also used and maintained in the same medium supplemented with the antibiotic hygromycin for selection of transfectants (200 µg/mL, Gibco).
RNA interference A549-Luc cell line
Twenty-four hours prior to transfection, 2.5 × 10 4 A549 Luc cells were seeded per well in 24-well tissue culture plates (Corning, NY, USA). The required amounts of siRNA duplexes were diluted up to 100 μL in HBG (Hepes Buffered Glucose: 20 mM Hepes pH 7.5, 5% glucose, sterile filtered). Nanofiber solutions were added and the samples were mixed and incubated 60 min at room temperature to favor association between siRNA and PDA-nanofibers.
Targeting luciferase (siLuc) or control (siCtl) siRNA-nanofiber solutions were then added onto the cells in serum free medium. After 4 h of incubation, the medium was replaced by fresh RPMI medium containing 10% FBS. For initial screening, experiments were done in duplicate, and then confirmed in quadruplicate assays. See were also prepared in HBG buffer and matured for 60 min. Naked siRNA diluted in the HBG buffer were also used as negative control. Cells were transfected in the absence of serum and after 4 h, serum was added (10% FBS). Luciferase or Lim-1 expression was analyzed after 48 hours.
Commercial transfection agent jetPRIME™ (POLYPLUS-transfection, Illkirch, France) was chosen as a positive control at 10 nM siRNA concentration using standard protocols from POLYPLUS-transfection, siRNA complexes being formed in provided jetPRIME buffer.
See Figure 
Luciferase quantification Quantification with automated luminometer
Luciferase gene expression was determined on cell lysates (100 µL 1/5 diluted lysis buffer:
Promega Cell Culture Lysis 5x Reagent). The luciferase activity was quantified on 2 μL of cell lysate (after a 5 minutes centrifugation at 14000 g) in white 96-well plates with the Centro LB luminometer (Berthold, Thoiry, France). Following parameters were used: 50 µL of the luciferase substrate (Luciferase Assay Substrate, Promega, France) were automatically distributed ahead of each measurement, plate shaken for 3 seconds then bioluminescence was quantified over 1 second. Luciferase activity was compared to non-transfected cells and with cells being transfected with control siRNA (siCtl, non-matching sequence).
Protein concentration in cell lysates was measured by using BCA assay kit (Interchim, Montluçon, France), according to manufacturer's instructions on 15 µL cell lysates. After expressing the luciferase activity as relative light units integrated over 10 s per mg of cell protein (RLU/10 s/mg protein), the luciferase gene silencing was calculated relative to the luciferase activity of non-transfected A549-luc cells.
Quantification by bioluminescence imaging
After 48h of transfection, the culture medium of 786-O cells expressing luciferase was supplemented with luciferin at 150 μg/mL (Promega) and the cell plates were incubated for 10 minutes in the dark before imaging. This period of time allows the oxidation of the luciferin and the emission of quantifiable photons by the action of the luciferase. The intensity of the bioluminescence is then evaluated using the "Fusion FX7" imager (VilberLourmat, Collegien, France) allowing the acquisition of the signal after 5 minutes of exposure and an Image capture with a cooled CCD camera.
Cell density
To evaluate the cytotoxicity of PDA-Nfs, we assessed cell density using the crystal violet staining method. Cells were fixed with 10% paraformaldehyde (Sigma-Aldrich) and then stained with 0.1% crystal violet dye (Sigma-Aldrich). After treatment with acetic acid at 33%, 
Histological analysis of the xenograft tumors and detection of PDA-Nfs
Harvested subcutaneous tumors from siRNA/PDA-Nfs injected mice were fixed in 10% neutral-buffered formalin and processed for histologic examination including embedding in paraffin, sectioning, and staining with hematoxylin and eosin. Four µm sections from selected paraffin were used for histopathology analysis to confirm the presence of PDA-Nfs. 
Western blot analysis
Protein extraction and membrane preparation were performed as described by Massfelder 
Biodistribution studies
The biodistribution of the fluorescent siRNA/PDA-Nf complexes was followed in Swiss CD-1 mice. They were treated by single i.p. injection and sacrificed 1 hour or 48 hours after administration of siLim1/PDA-Nfs by the TechMed'ill platform. No clinical signs of pain, discomfort or abnormal behavior were observed in the mice injected with the siRNA/PDANfs.
As described in main article no sign of inflammation or redness/rashes at the site of injection and no visible local accumulation of the red PDA-Nfs, neither at 1 hour nor at 48 hours after injection were observed. Fresh blood was withdrawn at 1 hour and 48 hours and blood films were prepared, then analyzed by fluorescence microscopy. Major organs were fixed in PBS- 
Statistical analysis
All values are expressed as mean ± s.e.m. Statistical analysis was performed using one-way ANOVA followed by the Student-Newman-Keul's test for multiple comparisons. A P<0.05 was considered significant (statistical analysis done with Prism 7™ scientific software by GraphPad™). Results are shown as mean ± s.e.m., n=3; ***P<0.001 from siCtl. Between N/P = 6 and 10 the zeta potential values are higher than 30mV, which stands often for colloidal stability. The aggregates at N/P = 2 have a negative zeta potential due to excess negative charge resulting from siRNA sticking on the surface of the PDA-Nfs. 
